Cart
sales@molnova.com
Palazestrant
CAS No. 2092925-89-6
Palazestrant( —— )
Catalog No. M36480 CAS No. 2092925-89-6
Palazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 1 mL x 10 mM in DMSO | 169 | In Stock |
|
| 5MG | 154 | In Stock |
|
| 10MG | 226 | In Stock |
|
| 25MG | 377 | In Stock |
|
| 50MG | 535 | In Stock |
|
| 100MG | 731 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NamePalazestrant
-
NoteResearch use only, not for human use.
-
Brief DescriptionPalazestrant (OP-1250) is an orally available and highly potent estrogen receptor antagonist and selective ER degrader with antitumor activity.
-
DescriptionPalazestrant is an antiestrogen and antineoplastic agent. Palazestrant in combination with a HER2 inhibitor, works on ER+/HER2+ cancer.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayEndocrinology/Hormones
-
TargetEstrogen Receptor/ERR
-
RecptorEstrogen/progestogen Receptor
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2092925-89-6
-
Formula Weight449.6
-
Molecular FormulaC28H36FN3O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESC(C(C)(C)F)N1[C@@H](C2=C(C=3C(N2)=CC=CC3)C[C@H]1C)C4=CC=C(OC5CN(CCC)C5)C=C4
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Harmon CL, et al. Methods of treating estrogen receptor-associated diseases such as ER+/HER2+ cancer using an estrogen receptor antagonist: World Intellectual Property Organization, WO2023283329. 2023-01-12.
molnova catalog
related products
-
CHF-4227
CHF-4227 is a novel, potent and selective estrogen receptor modulator that reduces cholesterol and LDL cholesterol concentrations.
-
Clomiphene citrate
A non-steroidal, a widely used fertility agent that inhibits estrogen receptor in the hypothalamus.
-
Fulvestrant
Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast Y in post-menopausal women with disease progression following anti-estrogen therapy.
